Impact of the COVID-19 Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection with SARS-CoV-2: prospective national cohort study, England

Abstract Background Streptococcus pneumoniae coinfection with influenza results in synergistic lethality, but there are limited data on pneumococcal coinfection with SARS-CoV-2. Methods Public Health England conducts invasive pneumococcal disease (IPD) and SARS-CoV-2 surveillance in England. IPD trends during 2000/01-2019/20 were analysed and cases between during February-June 2020 were linked with laboratory-confirmed SARS-CoV-2 infections. Multivariable logistic regression was used to assess risk factors for death. Results IPD incidence in 2019/20 (7.6/100,000; n=3,964) was 30% (IRR 0.70, 95%CI, 0.18-2.67) lower compared to 2018/19 (10.9/100,000; n=5,666) with large reductions observed across all age-groups during March-June 2020. The serotypes responsible for IPD during 2019/20 were similar to previous years. There were 160,886 SARS-CoV-2 and 1,137 IPD cases during February-June 2020, including 40 IPD/COVID-19 (0.025% [95%sCI, 0.018-0.034] of SARS-CoV-2 infections; 3.5% [95%CI, 2.5-4.8] of IPD cases), 21 with COVID-19 diagnosed 3-27 days after IPD and 27 who developed COVID-19 ≥28 days after IPD. Case-fatality rates (CFR) were 63.2% (25/40), 47.6% (10/21) and 33.3% (9/27), respectively (p<0.001). In addition to an independent association with increasing age and pneumococcal serotype group, CFR was 7.8-fold (95% CI, 3.8-15.8) higher in those with IPD/COVID-19 co-infection and 3.9-fold (95% CI, 1.4-10.7) higher in patients who developed COVID-19 3-27 days after IPD compared to patients with IPD only. Conclusions Large declines in IPD were observed following COVID-19 lockdown in England. IPD/COVID-19 confections were rare but associated with high CFR, mainly in older adults. The rarity, age distribution and serotype distribution of IPD/SARS-CoV-2 coinfections does not support wider extension of pneumococcal vaccination.

[1]  Felipe García,et al.  Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study , 2020, Clinical Microbiology and Infection.

[2]  R. Myers,et al.  Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020 , 2020, EClinicalMedicine.

[3]  K. Simon,et al.  Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit – High mortality rate in infected patients with haematologic malignancies , 2020, Journal of Clinical Virology.

[4]  M. Dimopoulos,et al.  Predictors of adverse prognosis in COVID‐19: A systematic review and meta‐analysis , 2020, European journal of clinical investigation.

[5]  D. MacFadden,et al.  Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis , 2020, Clinical Microbiology and Infection.

[6]  Céline Caserio-Schönemann,et al.  Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  J. Hewitt,et al.  The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study , 2020, The Lancet Public Health.

[8]  A. Deghmane,et al.  Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease , 2020, BMC research notes.

[9]  C. Houlihan,et al.  Nosocomial transmission of COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Lipsitch,et al.  Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study , 2020, BMC Medicine.

[11]  Sook-In Jung,et al.  Age-Related Morbidity and Mortality among Patients with COVID-19 , 2020, Infection & chemotherapy.

[12]  T. Burki England and Wales see 20 000 excess deaths in care homes , 2020, The Lancet.

[13]  D. Creer,et al.  COVID-19: a retrospective cohort study with focus on the over-80s and hospital-onset disease , 2020, BMC Medicine.

[14]  B. Song,et al.  CT Manifestations and Clinical Characteristics of 1115 Patients with Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis , 2020, Academic Radiology.

[15]  G. Cooke,et al.  Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  W. Lim,et al.  Co-infections in people with COVID-19: a systematic review and meta-analysis , 2020, Journal of Infection.

[17]  N. Zhang,et al.  A systematic review of chest imaging findings in COVID-19. , 2020, Quantitative imaging in medicine and surgery.

[18]  J. O’Grady,et al.  Co-infections: potentially lethal and unexplored in COVID-19 , 2020, The Lancet Microbe.

[19]  Kehu Yang,et al.  Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis , 2020, medRxiv.

[20]  A. Akbari,et al.  Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis , 2020, Archives of academic emergency medicine.

[21]  M. Mansournia,et al.  Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis , 2020, Microbial Pathogenesis.

[22]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[23]  N. Andrews,et al.  Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study , 2019, PLoS medicine.

[24]  R. Pebody,et al.  Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales , 2018, EClinicalMedicine.

[25]  S. Madhi,et al.  The role of bacterial vaccines in the prevention of influenza mortality. , 2018, The Lancet. Global health.

[26]  N. Andrews,et al.  Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. , 2018, The Lancet. Infectious diseases.

[27]  E. Klein,et al.  The frequency of influenza and bacterial coinfection: a systematic review and meta‐analysis , 2016, Influenza and other respiratory viruses.

[28]  V. Chow,et al.  Lethal Synergism between Influenza and Streptococcus pneumoniae , 2016, Journal of infectious pulmonary diseases.

[29]  W. Lim,et al.  Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia , 2015, European Respiratory Journal.

[30]  M. Weinstein,et al.  Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States , 2013, BMC Infectious Diseases.

[31]  N. Andrews,et al.  Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. , 2011, The Lancet. Infectious diseases.

[32]  F. Esper,et al.  Rate and influence of respiratory virus co-infection on pandemic (H1N1) influenza disease , 2011, Journal of Infection.

[33]  R. Guy,et al.  Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England, December 2010 to January 2011. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[34]  S. Madhi,et al.  Pneumococcal pneumonia and influenza: a deadly combination. , 2009, Vaccine.